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Background: This dissertation involves an evaluation of the effect of the Patient
Protection and Affordable Care Act (ACA) on diabetic medication adherence as the
Medicare Part D coverage gap begins to close.
Purpose: The dissertation’s primary research question: will medication
adherence for Humana Medicare Part D health plan members filling diabetic medications
at Humana’s mail order pharmacy improve as the coverage gap is incrementally closed
due to the ACA? The study had 3 objectives: 1) to evaluate diabetes medication
adherence of health plan members before they reach the coverage gap and then while
they are in the coverage gap, 2) to compare diabetes medication adherence between two
similar groups with differing benefit structures, one group with a gap in coverage as
opposed to a group with no benefit changes within the year and 3) to examine diabetes
medication adherence trend over multiple years as the coverage gap is closed.
Methods: A retrospective, pre-post cohort analysis with control group study
design was used to assess the study objectives. The control group consisted of low-
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income subsidy (LIS) members with no gap in coverage and the treatment group reached
the coverage gap.
Results: Brand and generic medication users exhibited decreases in adherence
once they entered the coverage gap although significant differences were seen for all
years in the brand cohort only. The control group exhibited better adherence than the
treatment group. The control group also exhibited stable adherence year over year while
the treatment group realized a decline.
Conclusions: The results of this study indicate that being in the coverage gap was
a significant indicator of a decrease in adherence for health plan members on brand
diabetic medications. While the study findings showed a decrease rather than an increase
in the treatment group medication adherence year over year, the results did indicate no
significant changes in the control group. The expectation would be that once the coverage
gap is fully closed in 2020, the treatment group would exhibit similar behavior. Both
groups exhibited high adherence overall suggesting the mail order dispensing channel
could have an effect on adherence.
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CHAPTER 1
INTRODUCTION
Background to the Study
Former Attorney General C. Everett Koop said, “Drugs don’t work in patients
who don’t take them (P. Ho, Bryson, & Rumsfeld, 2009).” Compliance, adherence and
persistence are terms commonly used to describe the patient’s reaction to medical advice
or instruction (Bailey & Kodack, 2011). Compliance describes a patient’s willingness to
follow a prescribed treatment regimen. Adherence, however, is the extent to which the
patient achieves an agreed upon treatment regimen without close supervision. Persistence
is the duration of time from initiation to discontinuation of therapy. Poor medication
adherence accounts for substantial deterioration of disease, death and increased health
care costs in the United States. Of all medication-related hospital admissions in the
United States, 33 to 69 percent result from poor medication adherence, with an estimated
cost of $100 billion a year (Osterberg & Blaschke, 2005).
Adherence to medication regimens has been observed since the time of
Hippocrates, when the effects of various potions were recorded with notations of whether
the patient had taken them or not (Osterberg & Blaschke, 2005). There are many ways to
measure medication adherence that involve both direct and indirect methods. Direct
methods include directly observed medication administration and detection of medication
levels in the blood while methods with indirect measurement are patient questionnaires,
pill counts and rate of refills (Osterberg & Blaschke, 2005).
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Medication non-adherence is a multifaceted issue that relates to both behavioral
and system barriers (Touchette & Shapiro, 2008). Behavioral barriers include social
support, cognition and personal health beliefs. System barriers include treatment
complexity (multiple medications/dosing schedule), system complexity (multiple
providers) and cost.

The Importance of Adherence in Public Health
The impact of poor medication adherence has an impact to the population in terms
of both health and cost. In 2009, a research brief by the New England Healthcare
Institute estimated that medication non-adherence, in addition to suboptimal prescribing,
drug administration and diagnosis could result in as much as $290 billion per year in
avoidable medical spending, equivalent to 13 percent of total U.S. health care
expenditures (New England Healthcare Institute, 2009). While a report released by
Express Scripts in 2014 estimated the cost at $337 billion, which equates to about one of
every nine healthcare dollars spent wasted due to non-adherence (Sundar, 2015). In fact,
non-adherence to prescribed medication regimens has been shown to result in $100
billion in costs related to excess hospitalizations alone (New England Healthcare
Institute, 2009) and accounts for as many as 40 percent of nursing home admissions
(Case Management Society of America, 2006). Clearly, poor adherence can lead to an
increase in acute healthcare resource utilization and result in the need for specialized and
costly long-term care.
In addition to the cost burden that medication non-adherence places on the
healthcare system, it can also be a cause of mortality. An analysis conducted in England
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attributed medication non-adherence to be a contributing factor in at least 25 percent of
suicides and homicides by people with mental illness (Priebe et al., 2010). It also is
estimated that a lack of adherence to regimens for heart disease is responsible for 125,000
deaths annually (McCarthy, 1998).
The adverse effects of poor adherence are both individual and societal (Giuffrida
& Torgerson, 1997). Non-adherence reduces the benefit of the preventive or curative
services of the therapy to the individual. The lack of adherence may cause unnecessary
diagnostic and treatment procedures, adding cost to the system and for the patient. Nonadherence to treatment for infectious disease can result in drug resistance and spread of
infection to others. This is especially relevant in the treatment of tuberculosis, a serious
public health concern. Poor adherence leads to more expensive treatment for the
individual patient as the disease progresses and increases the possibility of drug
resistance and threat of infection to the population at large. Another public health
example would be adherence to anti-rejection medications following organ
transplantation. Organs are a scare resource and when protocols are not followed, those
resources are wasted. In fact, a study in the 1980’s showed 18 percent of post-transplant
patients were non-adherent (Burns & Shaw, 2007). Of those 18 percent a majority (91
percent) lost the transplanted organ or died compared to 18 percent of patients in the
adherent group. Finally, non-adherence by individuals in clinical trials can result in
overestimations of therapeutic dosing, causing drug toxicity in adherent patients.
Although medication adherence has clear benefits to society and the individual,
the choice to be adherent lies primarily with the individual. Some reasons a person might
choose to be non-adherent to therapy include a decision to avoid potential serious side
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effects or on the basis that the patient disagrees with the treatment or even the diagnosis
itself (Priebe et al., 2010). There are potential benefits to non-adherence because it can
sometimes reduce the cost of treatment and adverse effects, especially if the treatment is
inappropriate (Giuffrida & Torgerson, 1997).
There are numerous barriers to adherence, many of which the patient may have no
control over. The World Health Organization (WHO) defines five categories of
medication related non-adherence (P. Ho et al., 2009). The first category is the health
system, which could include a lack of access to providers, poor communication between
the patient and provider or even a language barrier. The type of condition the patient has
is often a barrier to adherence. Patients who have diseases with no symptoms or physical
cues may have a difficult time remembering to take their medication. Patients who suffer
from mental illness may take their medications, start to feel better and stop taking it,
cycling through phases of adherence and non-adherence. The patient themself can be a
barrier to adherence. Studies have shown that adherence is lower in younger patients and
those of nonwhite race. Older patients may have mental impairments that hinder their
ability to be adherent or dexterity issues that would prohibit them from something as
simple as opening a child-protective bottle. The fourth category is therapy. For example,
patients on multiple drugs or drugs that require multiple doses a day are less likely to be
fully- adherent. Finally, a patient’s socioeconomic status can act as a barrier to adherence.
Low health literacy can result in an inability to understand directions on how or when to
take the medication and higher medication costs can hinder the patient’s ability to even
obtain the medication on a regular basis.
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Table 1. WHO categories of non-adherence (P. Ho et al., 2009)
Categories of
non-adherence
Health System
Condition
Patient
Therapy
Socioeconomic

Examples
Poor quality of provider-patient relationship; poor communication;
lack of access to healthcare; lack of continuity of care
Asymptomatic chronic disease (lack of physical cues); mental
health disorders (e.g. depression)
Physical impairments (e.g. vision problems or impaired dexterity);
cognitive impairment; psychological/behavioral; younger age;
nonwhite race
Complexity of regimen; side effects
Low literacy; higher medication costs; poor social support

The Importance of Adherence in Diabetes
Medication adherence is especially important for chronic diseases like diabetes,
where medication can prevent or delay the onset of complications, reduce hospitalization
risks and costs and improves quality of life for patients (Sacks, Burgess, Cabral, Pizer, &
McDonnell, 2013). Diabetes is increasingly common among seniors, with prevalence
rates estimated at 26.7 percent and roughly 390,000 cases diagnosed annually (Sacks et
al., 2013). Generic medications are used as first-line and second-line therapies, with a 30day supply of metformin, a biguanide, and sulfonylureas (glimepiride, glipizide,
glyburide) readily available as inexpensive $4 cash generics. Higher priced branded
products like sitagliptin (marketed only as Januvia and not yet generically available),
with average 30-day cash prescription prices exceeding $300, are recommended for more
complex or advanced disease.
The long-term complications of diabetes, particularly type 2 diabetes, present a
difficult challenge that requires comprehensive management of glycemia and a myriad of
cardiovascular (CV) risk factors and comorbidities (Bailey & Kodack, 2011).
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Hemoglobin A1c (HbA1c) levels reflect the glucose concentration in the blood. A high
glucose concentration equates to a higher HbA1c. Levels of HbA1c are not influenced by
daily fluctuations in the blood glucose concentration rather reflect the average glucose
levels over the prior six to eight weeks. Therefore, HbA1c is a useful indicator of how
well the blood glucose level has been controlled in the recent past and may be used to
monitor the effects of diet, exercise and drug therapy on blood glucose in diabetic
patients. In healthy, non-diabetic patients the HbA1c level is less than 7 percent of total
hemoglobin. It has been demonstrated that the complications of diabetes can be delayed
or prevented if the HbA1c level can be kept close to 7 percent (American Diabetes
Association, 2015). In general, values should be kept below 8 percent.
Although an extensive and effective range of medications options exist to address
these issues, only slightly more than half of patients achieve a HbA1c target of less than
7.0 percent and about two-thirds of patients die of CV disease (Bailey & Kodack, 2011).
There are established protocols, guidelines and algorithms to accommodate the needs of
most patients under a majority of circumstances. However, medication adherence is often
a neglected issue in this patient population. Table 2 outlines the available therapies used
to manage Type 2 diabetes, the initial dose and the approximate cash price for a 30-day
supply as of June 2015.
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Table 2. Drugs for Type 2 Diabetes (Pharmacist's Letter/Prescriber's Letter, June 2015)
Class

Specific Agents

Alpha-glucosidase
inhibitor

Acarbose (Precose, others)

Amylin analog
Biguanide
Dipeptidyl
peptidase-4 (DPP4) inhibitor or
incretin enhancer

Glucagon-like,
peptide-1 (GLP-1)
agonist or incretin
mimetic

Insulin

Initial Dose (Approximate cost for 30-day
supply)
Acarbose: 25mg PO TID ($45)

Miglitol (Glyset)
Pramlintide (Symlin)

Miglitol: 25mg PO TID ($145)
Pramlintide: 60mcg SC prior to major meals
($590)
Metformin: 500mg PO BID or 850mg PO once
daily (less than $20/month)
Alogliptin: 25mg PO once daily ($310)

Metformin (Glucophage,
Glucophage XR)
Alogliptin (Nesina)
With metformin (Kazano)
With pioglitazone (Oseni)
Linagliptin (Tradjenta)
With metformin (Jentaduetno)
With empagliflozin
(Glyxambi)

Linagliptin: 5mg PO once daily ($330)

Saxagliptin (Onglyza)
With metformin (Kombiglyze
XR)

Saxagliptin: 2.5 or 5mg PO once daily ($325)

Sitagliptin (Januvia)
With metformin (Janumet,
Janumet XR)
With simvastatin (Juvisync)
Albiglutide (Tanzeum)

Sitagliptin: 100 mg PO once daily ($330)

Dulaglutide (Trulicity)

Dulaglutide: 0.75mg SC once weekly ($490)

Exenatide (Byetta)

Exenatide: 5mg SC BID ($480)

Exenatide extended-release
(Bydureon)

Exenatide extended-release: 2mg SC once weekly
($475)

Liraglutide (Victoza)

Liraglutide: 0.6mg SC daily x 1 week then 1.2mg
SC once daily ($430)
Varies

Albiglutide: 30mg SC once weekly ($325)

Rapid-acting insulin: lispro
(Humalog), aspart (NovoLog),
glulisine (Apidra)
Regular short-acting insulin:
Humulin R, Novolin R
Intermediate-acting (basal)
insulin: NPH (Humulin N,
Novolin N)
Long-acting (basal) insulin:
glargine (Lantus), detemir
(Levemir)
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Class

Specific Agents

Insulin
(continued)

Premixed insulin:
Rapid acting: NovoLog Mix
70/30, Humalog Mix 75/25 or
50/50
Short-acting: Humulin 70/30,
Novolin 70/30
Nateglinide (Starlix)

Meglitinide

Sodium-glucose
cotransporter-2
(SGLT2) inhibitor
or "flozins"

Sulfonylurea-first
generation

Sulfonylureasecond generation

Thiazolidinedione
(TZD)

Initial Dose (Approximate cost for 30-day
supply)
Varies

Nateglinide: 60 to 120mg PO TID ($105)

Repaglinide (Prandin, others)
With metformin (PrandiMet)
Canagliflozin (Invokana)
With metformin (Invokamet)

Repaglinide: 0.5, 1 or 2mg PO TID ($50)

Dapagliflozin (Farxiga)

Dapagliflozin: 5mg PO once daily ($340)

Empaglifozin (Jardiance)
With linagliptin (Glyxambi)
Chlorpropamide (Diabinese,
others)

Empaglifozin: 10mg PO once daily ($340)

Tolazamide (Tolinase, others)

Tolazamide: 250mg PO once daily ($48)

Tolbutamide (Orinase, others)
Glyburide (Diabeta, Glynase,
Micronase, others)
With metformin (Glucovance)

Tolbutamide: 1g PO once daily ($70)
Glyburide: 2.5mg PO once daily (less than
$10/month)

Glipizide (Glucotrol,
Glucotrol XL, others)

Glipizide: 5mg PO once daily (less than
$10/month)

Glimepiride (Amaryl, others)
With metformin (Amaryl M)
With pioglitazone (Duetact)
With rosiglitazone
(Avandaryl)
Pioglitazone (Actos)
With metformin (ActosMet,
ActosMet XR)
With glimepiride (Duetact)
With alogliptin (Oseni)

Glimepiride: 1 mg PO once daily (less than
$10/month)

Rosiglitazone (Avandia)
With metformin (Avandamet)
With glimiperide (Avandaryl)

Rosiglitazone: Initial 4mg PO once daily ($115)

Canagliflozin: 100mg PO once daily ($340)

Chlorpropamide: 100 to 200mp PO once daily
(less than $20/month)

Pioglitazone: Initial 15mg PO once daily (less
than $20)
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Extensive evidence indicates that rigorous control of blood glucose is associated
with a reduction in long- term vascular complications in patients with type 2 diabetes
(Bailey & Kodack, 2011). Greater adherence to treatment regimens has shown to improve
metabolic control outcomes. Indeed, non-adherent patients are at increased risk for the
development of vascular complications, hospitalizations and death. Researchers
conducting a study of adherence in a medically indigent population with type 2 diabetes
noted that each 10 percent decrease in adherence was accompanied by a positive 0.14
percent increase in HbA1c (Bailey & Kodack, 2011). In addition, the benefits of
improved adherence have been linked to fewer emergency department visits and fewer
inpatient admissions. Patients with diabetes who did not regularly take their diabetes
medications as prescribed were 2.5 times more likely to be hospitalized than those who
were adherent more than 80 percent of the time (Lau & Nau, 2004).
Figure 1. Relationship between Adherence and Hospitalization in Diabetes (Lau & Nau,
2004)	
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The Medicare Modernization Act of 2003
The Medicare Modernization Act (MMA) of 2003 allowed Medicare expansion in
2006 to offer voluntary outpatient prescription drug coverage ("The Medicare
Prescription Drug Benefit Fact Sheet," 2014). All 54 million people on Medicare are
eligible to enroll in this benefit offered through private plans approved by the federal
government. The Medicare drug benefit is offered through stand-alone prescription drug
plans (PDP) covering only outpatient medications and Medicare Advantage prescription
drug (MAPD) plans covering all Medicare benefits including drugs.
Enrollment in Medicare drug plans is voluntary, with the exception of those who
are dually eligible for both Medicare and Medicaid and certain other low-income health
plan members who are automatically enrolled in a PDP if they do not choose a plan on
their own ("The Medicare Prescription Drug Benefit Fact Sheet," 2014). In 2014, more
than 37 million Medicare health plan members were enrolled in Medicare Part D plans,
up from 26 million in 2009. Of this total, about two-thirds were enrolled in a stand-alone
PDP and one-third enrolled in a Medicare Advantage drug plan.
A unique feature to the Medicare Part D benefit is the coverage gap, sometimes
referred to as the “donut hole”. The coverage gap was included because the cost of
providing continuous coverage with no gap would have exceeded the budgetary limit
imposed on the legislation when the Medicare drug benefit was established (Hoadley,
Thompson, Hargrave, Cubanski, & Neuman, 2008). The coverage gap is a benefit phase
where the enrollee incurs all or most of the drug cost until they hit a certain dollar limit.
The Medicare health plan members who are eligible for a low-income subsidy or dually
eligible for both Medicare and Medicaid are not subject to the coverage gap.
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In 2013, most PDPs (69 percent) offered little or no gap coverage beyond that
required by law (Hoadley, Summer, Hargrave, & Cubanski, 2013). The plans offering
extra gap coverage have premiums that are almost twice as expensive as those that offer
no coverage and therefore fewer enrollees. In fact, enrollment in these plans has remained
low since 2006 with only 5-6 percent of PDP enrollees choosing a plan that includes
some type of coverage in the gap. In 2013, only 35 percent of MAPD enrollees were in a
plan that had extra gap coverage, which was up from 27 percent in 2006.

The Patient Protection and Affordable Care Act
In 2010, the Patient Protection and Affordable Care Act (ACA) made significant
changes to the coverage gap. Table 3 outlines the benefit phases, coverage limits and
coverage gap changes from 2009 to 2014. Standard Part D Plans have a deductible phase,
followed by an initial coverage phase where the enrollee pays 25 percent of the drug cost
up to a set coverage limit. The enrollee then enters the coverage gap, where until 2010 the
enrollee was responsible for 100 percent of the drug costs until they entered the
catastrophic phase. The ACA mandates that the coverage gap will incrementally close
until it is eliminated in 2020.
Figure 2. Medicare Part D Benefit Phases
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Among Part D enrollees who used prescription drugs in 2009 and did not receive
a low-income subsidy, about one in five (19 percent) had spending high enough to reach
the coverage gap (Hoadley, Summer, Hargrave, & Cubanski, 2011). Overall, about 3.4
million health plan members (12 percent of the total population of Part D enrollees)
reached the coverage gap and faced the full cost of their prescription drugs in 2009.
Table 3. 2009-2014 Medicare Part D Standard Benefit Model Plan Parameters
(Q1Group)
Medicare
Part D Phase
Benefits
Deductible
Initial
Coverage

Coverage
Gap

Plan Year
Responsibility
Member Pays
Member Pays
Plan Pays
Coverage
Limit
Member Pays
Plan Plays
Manufacturer
Pays

2009
$295
25%
75%

2010
$310
25%
75%

2011
$310
25%
75%

2012
$320
25%
75%

2013
$325
25%
75%

2014
$310
25%
75%

$2,700

$2,830

$2,840

$2,930

$2,970

$2,850

100%
0%

Brand Drugs
100%
50%
0%
0%

50%
0%

47.5%
2.5%

47.5%
2.5%

$250

50%

50%

50%

0%

50%

Generic Drugs
100%
93%
0%
7%

Member Pays
100%
86%
79%
72%
Plan Pays
0%
14%
21%
28%
Coverage
$6,154 $6,440 $6,484 $6,730 $6,955 $6,691
Limit
Member Pays
5%
5%
5%
5%
5%
5%
Catastrophic
Plan Pays
15%
15%
15%
15%
15%
15%
Coverage
Medicare
85%
85%
85%
85%
85%
85%
Pays
*Coverage Limit amount is Total Drug Costs (Plan paid + Health Plan Member paid)
The Effect of Cost-Sharing and Copayments on Adherence
	
  
Patterson, et al. examined the association of higher copayments to a greater risk of
non-adherence specifically targeting beta blocker utilization in heart failure patients 50
years and older (Patterson, Blalock, Smith, & Murray, 2011). From a database of 38
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million unique individuals, the researchers pared down the cohort to 2,359 relatively
compliant heart failure patients.
The researchers found that patients with the highest copayment level ($26-30) as
compared with the lowest copayment level (under $1) had on average a 7 percent less
medication supply of beta-blockers over the course of a year. The researchers also found
that patients with the higher copayment tier showed an increased risk of non-adherence.
This study did have several limitations including a small sample size in the upper limit
copayment tier and selection factors that could not be controlled.
Li, et al. and Zhang, et al. conducted studies that examined cost as a barrier to
adherence when Medicare Part D patients reach the coverage gap and incur 100 percent
cost share of their medications (Li, McElligott, Bergquist, Schwartz, & Doshi, 2012;
Zhang, Baik, & Lave, 2013). Researchers in both studies utilized a pre-post design and a
5 percent sample of Medicare health plan members. Li, et al. looked specifically at
patients with hypertension and hyperlipidemia. They utilized a control group of lowincome subsidy patients who would have no benefit changes in the gap phase. The other
three groups consisted of patients with no coverage in the gap, those with generic only
coverage and patients with brand and generic coverage in the gap.
While in the coverage gap, patients in the no-coverage group had higher average
out-of-pocket costs per prescription ($31 for anti-hypertensives and $79 for lipidlowering drugs), as did those in the generic-only coverage group ($29 for antihypertensives and $58 for lipid-lowering drugs). The remaining groups had no substantial
change in copayments. Compared to the control group, the no-coverage group had a
statistically significant decrease in the number of brand and generic prescriptions, which
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would translate to a decrease in adherence. The generic-only coverage group had a
statistically significant decrease in brand prescriptions but not adherence to generic
prescriptions.
Zhang, et al. examined a population with heart failure and/or diabetes through the
coverage gap. As in the prior study, a low-income subsidy group was utilized as a control
but only 2 other groups were identified: no coverage through the gap and generic only
coverage. Researchers utilized propensity score matching for age, sex, race and number
of Elixhauser comorbidities. The Elixhauser comorbidity index is a measurement tool
that defines 30 comorbid (i.e., co-existing) conditions using ICD-9 codes. This
instrument was developed in order to be used with large administrative data sets
(Elixhauser, Steiner, Harris, & Coffey, 1998).
The study conducted by Zhang, et al. had three important findings. First, when
matched to the comparison group, there were statistically significant reductions in all
studied outcomes present in both study groups: probability of using a drug, mean number
of monthly prescriptions filled and monthly pharmacy spending. However, the nocoverage group showed a greater decrease in medication adherence than those with
generic drug coverage only in the gap. Second, the overall decrease in monthly
medications amounts and spending was primarily due to a decrease in brand medication
utilization. For example, those without drug coverage in the gap reduced their overall
medication use by 0.85 medications per month (75 percent brand name/25 percent
generic). This group decreased its monthly pharmacy spending by $73.15 ($66.65 brand
name/$6.40 generic). Third, those with generic only coverage in the gap reduced their use
of brand-name drugs but did not compensate for the decrease by increasing their use of
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generic drugs. In fact, they also decreased their use of generic drugs slightly but
negligibly.
These studies are significant because they establish a relationship between cost
and medication adherence. In fact, researchers of a 2004 RAND study found that
doubling copayments for medications reduced adherence by 25 to 45 percent (Goldman,
2004). As patients’ use of medications declined due to increased copayments, emergency
room visits increased 17 percent and hospital stays rose 10 percent among patients with
chronic conditions such as diabetes, asthma or gastric acid disorder.

Proposed Reform Effects
In 2013, two studies were published with focus on what may happen to adherence
for patients on anti-diabetic medication when the coverage gap closes (Sacks et al., 2013;
Zeng, Patel, & Brunetti, 2013). Researchers in both studies share the hypothesis that
closing the coverage gap thereby decreasing costs for patients will result in better
medication adherence. The Zeng, Patel & Brunetti study analyzed 2 cohorts of patients:
one group before any reform measures were enacted in 2010 and one group when brand
drugs were covered at 50 percent through the gap in 2011. Pharmacy claims data was
used for analysis and medication adherence was measured by portion of days covered
(PDC).
Zeng, et al, found that the average copayment in the coverage gap decreased by
27 percent from 2010 to 2011 and patients with no coverage or partial coverage in the
gap showed improved medication adherence in 2011 over 2010. However, patients with
full coverage in the gap showed unchanged adherence year over year.
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Sacks, et al. utilized 2 cohorts consisting of low income and non-low income
while logistic regression was used to model the likelihood of adherence to oral antidiabetic medications. The researchers concluded that the elimination of the coverage gap
would not affect generic utilization but should increase adherence for those who utilize
brand medications.
In 2012, a poster titled “Impact of the Affordable Care Act on Medication
Adherence in a Population of Medicare Part D Beneficiaries” was presented at the
Academy for Managed Care Pharmacy (AMCP) conference (Brown, Ward, & Yihua,
2012). The objectives of the study were to assess the impact of changes in the Medicare
Part D Coverage gap on adherence to brand and generic medications across plan years.
The researchers looked at Humana Medicare Part D health plan member utilization of
diabetic and anti-platelet medications between 2009 and 2012. They found the ACA is
modestly improving adherence across plan years and during the Medicare coverage gap
for brand medications while adherence to generic diabetes medications showed no
significant improvement.

Statement of the Problem
Prior research has been conducted on associations between medication adherence
and copayment levels in the Commercially insured population (Patterson et al., 2011).
Researchers have also studied the effect of the Part D coverage gap on medication
adherence (Li et al., 2012; Zhang et al., 2013) and how proposed coverage gap reform
may influence adherence (Sacks et al., 2013; Zeng et al., 2013). However, little research
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has been published regarding the ACA’s effect on medication adherence in the coverage
gap utilizing actual claims data.

Purpose of the Study
The main goal of this study is to examine how a public policy can affect
medication adherence in a subset of a population. In order to achieve this goal, the study
has 3 objectives: 1) to evaluate diabetes medication adherence of health plan members
before they reach the coverage gap and then while they are in the coverage gap, 2) to
compare diabetes medication adherence between two similar groups with differing
benefit structures, one group with a gap in coverage as opposed to a group with no
benefit changes within the year and 3) to examine diabetes medication adherence trend
over multiple years as the coverage gap is closed.
Medication adherence is the primary outcome measure of this study. Adherence
will be calculated by examining pharmacy claims data and using portion of days covered
(PDC), which is the method endorsed by the Pharmacy Quality Alliance (PQA) (Nau). If
a health plan member has enough medication to cover 80 percent of the measurement
period, that health plan member will be considered adherent. Based on numerous studies
of the relationship of medication adherence and healthcare outcomes, PQA selected 0.8
(or 80 percent) as the threshold above which the patient can be considered to be adherent
for most classes of chronic medications.
To the best of my knowledge, this is one of only a handful of studies to utilize
real-world claims data to examine the affect of the ACA on medication adherence in the
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Medicare Part D coverage gap. The study also provides the opportunity to add to the
wealth of literature around cost related non-adherence in the Medicare population.

Research Question and Hypotheses
Will medication adherence for Humana Medicare Part D health plan members
filling diabetic medications at Humana’s mail order pharmacy improve as the coverage
gap is incrementally closed due to the Patient Protection and Affordable Care Act
(ACA)?
Research Hypothesis 1: Diabetes medication adherence will decrease when health
plan members are in the coverage gap.
Null Hypothesis 1: There will be no change to diabetes medication adherence
when a health plan member enters the coverage gap.
Research Hypothesis 2: Diabetes medication adherence of the control group will
be better than the study group.
Null Hypothesis 2: There will be no statistically significant difference in
medication adherence between the groups.
Research Hypothesis 3: Diabetes medication adherence in the coverage gap will
show significant improvement for brand drugs year over year as the coverage gap closes.
Null Hypothesis 3: Diabetes medication adherence will not show significant
improvement for brand drugs.
Research Hypothesis 4: Diabetes medication adherence in the coverage gap will
show slight improvement for generic drugs year over year as the coverage gap closes.
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Null Hypothesis 4: Diabetes medication adherence will not show slight
improvement for generic drugs.

Summary
Medication adherence is an essential part of managing chronic disease. Poor
medication adherence results in additional costs to the healthcare system, a decreased
quality of life for the patient and can even result in death. For patients with diabetes,
medication adherence plays a vital role in managing blood glucose levels. Specifically, it
has been documented that each 10 percent decrease in adherence was accompanied by a
positive 0.14 percent increase in HbA1c. Furthermore, diabetic patients who did not
regularly take their diabetes medications were 2.5 times more likely to be hospitalized
than those who followed their prescribed treatment regimens more than 80 percent of the
time.
Medicare is a federal insurance program established in 1965 providing health
insurance to Americans ages 65 and older and to individuals under age 65 with specific
disabilities or end-stage renal disease. In order to increase Medicare health plan
members’ access to medications and help lower their prescription drug costs, the
Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003
introduced a prescription drug benefit referred to as ‘Medicare Part D’. Medicare Part D
has been structured to include substantial cost sharing by way of deductibles, copayments and coinsurance.
A significant amount of research has been dedicated to understanding the impact
of cost sharing on prescription drug utilization, medication adherence and health
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outcomes. A review of the literature indicates that cost sharing has also been associated
with decreased medication adherence, increased costs and increased out-of-pocket
expenses for health plan members. As the coverage gap closes, it provides a unique
opportunity to examine the effect of lessening the cost burden on medication adherence.
Details of the theoretical framework used to assess the study objectives are provided in
Chapter 2.
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CHAPTER 2
LITERATURE REVIEW
Theoretical Framework
The objectives in this study will be analyzed using the framework provided by the
economic theory and Andersen's Behavioral Model of Health Services Use. Both theories
offer a framework by which to examine health services utilization with respect to cost
and other variables. The economic theory points toward cost as a driver for behavior
while Andersen’s model includes a range of factors and feedback loops that ultimately
affect health care use and subsequent outcomes.

Economic Theory
Economic theory postulates that, when a patient is charged the full price of a
prescription medication and has adequate information to weigh the medication’s benefits
versus adverse effects, they will consume an optimal amount of the medication, given
their priorities and income constraints (Gibson, Ozminkowski, & Goetzel, 2005). The
theory assumes that rational patients will evaluate both the costs and benefits of a
medication compared with other methods of producing health and will utilize
combinations of these that maximize their health with respect to their income limitations.
It is possible that a patient who obtains insurance coverage that includes a
prescription benefit may be motivated to consume more medications than normal once
the cost barrier is removed and the price to the patient is lower than full price (Gibson et
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al., 2005). Therefore, raising the price of the medication through higher levels of cost
sharing can have various economic and behavioral effects.
Increasing cost to the patient can result in a change in consumption. As cost
sharing shifts to the patient, the patient moves up the demand curve and closer to the
economically optimal amount (Gibson et al., 2005). This ultimately results in a reduction
in consumption of medication. In terms of this study, as patients move into the coverage
gap and bear the full cost of the medication, it would be reasonable to expect some
patients to change their utilization patterns. For example, a patient could change
consumption from taking a medication twice daily as prescribed to once daily. In this
study, medication adherence for the health plan members was calculated prior to reaching
the coverage gap and then while in the coverage gap to look for a change in medication
utilization and consumption.
Another economic effect as a result of higher costs is substitution. Patients are
likely to search for less expensive substitutes as the prices of prescription medications
rise (Gibson et al., 2005). Therefore, if they discover a suitable substitute, patients are
likely to consume smaller quantities of prescription medications and larger quantities of
the substitute. Patients who utilize brand name medications may consider switching to a
generic alternative or over the counter product once they reach the coverage gap.
An increase in cost to the patient may cause them to consider the value of the
medication. A price increase would decrease the likelihood that drugs of low value, for
which the cost exceeds the perceived benefit to the patient, would be used (Gibson et al.,
2005). Conversely, patients would be price insensitive for high-value drugs, such as those
that are perceived as life sustaining, and would be expected to continue to fill
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prescriptions. However, this assumes that consumers have adequate information to
evaluate both the benefits and costs of drugs, which this study will lack sufficient data to
establish.

Andersen's Behavioral Model of Health Services Use
Andersen's Behavioral Model of Health Services Use was originally developed in
1968 and has since been modified multiple times (Andersen, 1995). The foundation of
the model lies in the premise that outcomes are dependent on environment factors,
population characteristics and health behavior factors. The 1995 modified model, as
shown below, is most frequently used in studies assessing health services use.

Figure 3. Andersen’s Behavioral Model of Health Service Use (Andersen, 1995)
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Environment factors, not present in the initial model, are an important input for
understanding the use of health services and refer to a combined measure of health care
system factors and external environment factors (Andersen, 1995). Health care system
factors include dynamics related to accessible health care resources, their organization in
the health care system that impact health services use and national health policy. External
environment factors refer to physical, political and economic components in a health care
system that impact use of health care services.
Population characteristics signify predisposing factors, enabling resources and
need (Andersen, 1995). Predisposing factors involve demographic variables (age, gender)
that represent biological imperatives suggesting the likelihood that people will need
health services and social structure (education, marital status, race/ethnicity, occupation)
that determine the status of a person in the community, ability to cope with health
problems and capacity to control resources to deal with health issues. An individual’s
health beliefs are also a predisposing factor. Health beliefs are attitudes, values and
knowledge that people have about health and health services that influence their
perception of need and use of health services. Enabling resources include accessibility
and availability of family and community resources such as income, health insurance, a
regular source of care, travel to services and waiting times. Need factors refer to both
perceived and evaluated need. Perceived need is an individual’s judgments of their health
status, how they experience symptoms of illness and whether or not they judge their
problems to be of sufficient magnitude to seek professional help. Evaluated need
represents professional judgment about that person’s health status and the need for
medical care.
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Health behavior factors represent a compound measure of personal health
practices such as diet and exercise interacting with the use of formal health services
including type, site, purpose and coordinated services in an episode of illness (Andersen,
1995).
Outcomes include perceived and evaluated health status and consumer
satisfaction (Andersen, 1995). Perceived health status reflects the health status, as
understood by the population itself while evaluated health status refers to the health status
as evaluated by professionals. Consumer satisfaction is a clear outcome of health services
including convenience, availability, financing, provider characteristics and quality of
care. The feedback loops in the model reflect the dynamic and recurrent nature of a health
services model.
A major contribution of Andersen’s model is the proposed measures of access.
Andersen presents four concepts within access that can be viewed through the conceptual
framework (Andersen, 1995). Potential access is the presence of enabling resources or
those means that allow the individual to seek care. Realized access is the actual use of
care. Equitable access occurs when demographic characteristics and need regulate who
obtains healthcare services. Whereas, inequitable access is a result of social structure (e.g.
ethnicity), health beliefs and enabling resources (e.g. income) determining who receives
medical care.
Andersen also introduces the concept of mutability of his factors (Andersen,
1995). To be considered useful for promoting equitable access, a variable must be
mutable or point to policy that might bring about behavior changes. For example,
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demographic variables have low mutability since age cannot be altered to change
utilization. Social structure is also low because ethnicity cannot be changed and
occupational/educational status is not easily transformed. Health beliefs are assigned
medium mutability because they can be altered and sometimes affect behavior change.
The RAND corporation study (Goldman, 2004) changed a highly mutable factor by
doubling copayments. This change resulted had a significant impact on health services
utilization as medication adherence declined.
Andersen’s model presents a broad framework of various factors that influence
health services utilization. In theory, all variables described in the model would be
measured to adequately assess health care utilization but this study utilizes pre-existing
data from a database and data required to assess each variable is not readily available. For
purposes of this study, the Andersen’s model framework serves as a theoretical guide to
assess the impact of the Medicare Part D coverage gap on Medicare health plan
members’ diabetic medication adherence, based upon the availability of the data. Figure 4
illustrates the model with variables included in this study.
Environment factors indicate a measure of external environment factors and
health care system factors, such as national policy. In this study, the national policies of
interest are the ACA and the Medicare Part D coverage gap limits set by the Center for
Medicare and Medicaid Services (CMS).
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Figure 4. Andersen’s Behavioral Model of Health Service Use (with variables used in
this study) (Andersen, 1995)
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Predisposing factors, such as demographic variables were easily assessed in this
study, including age, gender and race/ethnicity. Data representing social status, such as
marital status, education, occupation, co-morbidities and an individual’s health beliefs
and attitudes, were not available. The enabling resource considered in this study was
prescription drug insurance, as an individual’s access to a prescription drug benefit might
influence their medication utilization. Need factors refer to an individual’s perceptions of
their health status and their need for medical care. While the data does not provide a
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direct measurement of need factors, an individual’s choice to fill their diabetic
medication might be reflective of their perception of their health status and their need for
medical care. Therefore, filling diabetic medication in January of the respective plan year
was used as a need factor in this study.
Health behavior factors are a compound measure of an individual’s personal
health practices and health services use. Information related to the health plan member’s
personal health practices was not available in the data. However, the health behavior
assessed in this study refers to an individual’s prescription refill behavior and medication
adherence before they reach the coverage gap and while in the coverage gap phase of
their benefit. While health behavior assessment reflects the desired outcome to be
measured in this study, the data available for this study did not allow for measurement of
the outcomes listed in Andersen’s health behavior model and were abridged at
measurement of health services use, (i.e. medication adherence).
The aim of this study was to assess the impact of the Medicare Part D coverage
gap on medication adherence by using a methodologically sound research design
theoretically guided by the economic theory and Andersen's Behavioral Model of Health
Services Use. The goal of the research was to accurately identify when a health plan
member enters the coverage gap, incorporate health plan pharmacy data, include a control
group, account for confounding variables, use a validated measure of adherence and
apply statistically sound techniques for data analyses. Details of the methods used to
assess the study objectives are provided in chapter 3.
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CHAPTER 3
METHODS
	
  
Study Design
A retrospective, pre-post cohort analysis with control group study design was
used to assess the study objectives. The study objectives examined medication adherence
of health plan members enrolled in a health plan with no prescription drug coverage
during the coverage gap (study group) compared with that of health plan members
enrolled in a plan with no coverage gap (control group). The study objectives also
examined medication adherence of the study group before they enter the coverage gap
and while they are in the coverage gap. Pharmacy claims data from a large managed care
organization with over 7 million lives and spanning 50 states was utilized. Data was
extracted for the period January 1, 2009 to December 31, 2014. All analyses were
conducted utilizing SAS Enterprise Guide version 5.1.

Population
The population of interest in this study consisted of Humana Medicare Part D
health plan members who reached the coverage gap benefit phase and utilized Humana
mail order pharmacy to fill diabetic medications between 2009 and 2014. It should be
noted that Humana mail order does not offer auto-refill for Medicare members but does
outreach to members to encourage a refill when eligible. The comparison group consisted
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of Humana Medicare Part D health plan members who did not face a gap in coverage at
any period during the study years and utilized Humana mail order pharmacy to fill
diabetic medications.
Study participants included Medicare health plan members enrolled in a Medicare
Advantage prescription drug (MAPD) or Medicare Part D prescription drug (PDP) plan
offered by Humana, Inc. In order to qualify for the study group, health plan members
must have been enrolled in a plan that offered no coverage in the gap. In order to be
considered for inclusion in the control group, health plan members must have been
enrolled in a plan with no lapse in benefit (i.e., the coverage gap), such as Low Income
Subsidy (LIS) Medicare Part D plans.
Humana, Inc. is the second largest national insurer of Medicare Part D health plan
members. Total Medicare Part D enrollment as reported by CMS for years 2007 and 2014
is presented in Figure 5 (Medicare Payment Advisory Commission, 2015). During that
time, Humana retained a significant amount of market share at 18 and 17 percent,
respectively.
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Figure 5. Enrollment by plan sponsor (Medicare Payment Advisory Commission, 2015)

Eligibility Criteria
Health plan members were eligible for inclusion in the analysis if they had at least
one prescription claim for a medication of interest at Humana’s mail order pharmacy
during the month of January in plan years 2009, 2010, 2011, 2012, 2013 or 2014. The
date of the first fill of a study medication during the intake period was defined as the
index fill.
Health plan members in the study group were Medicare Part D prescription drug
plan (PDP) or Medicare Advantage (MAPD) health plan members aged 18 to 89 years at
the beginning of the plan year with 12 months continuous enrollment in a plan year.
Eligible health plan members must have reached the Medicare coverage gap between
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April 1st and September 30th during the respective plan year. The April to September
time period is used in order to measure medication adherence both pre-coverage gap and
within the coverage gap. Eligible health plan members for the comparison group must
have been enrolled in a low-income subsidy (LIS) PDP or MAPD plan that offered
continuous benefits with no deductible or coverage gap phases.
Adherence to generic and brand medications was calculated separately. Generic
formulations of the study drugs were identified using a generic product indicator (GPI)
variable for each drug in each year of the database. Eligible health plan members had a
fill of one or more of the study medications. The diabetes medications of interest include
all medications listed in Table 2 with the exception of insulin. Adherence was calculated
using the days supply field found on the pharmacy claim. Pharmacy claims data for
insulin does not have a quantifiable days supply. Moreover, it is not possible to calculate
a PDC for any medication taken on an as needed basis or with a variable dosage unit per
day (McKenzie, Lenz, Gillespie, & Skradski, 2012). Injectable medications with a fixed
unit dose were included.
The disease of interest in this study was Type 2 diabetes but medical data was not
available for all health plan members to confirm a diagnosis by way of medical claims.
Daily management of Type 1 diabetes is managed by balancing insulin, diet and exercise
(Mehta et al., 2015). Therefore, it was assumed that excluding insulin from the study
medications limited the population to those diagnosed with Type 2 diabetes.
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Description of study variables
a) Independent Variable
The independent variable in this study was the coverage gap status of individuals.
The coverage gap status was evaluated at two levels: pre- gap and gap. Pre-coverage gap
refers to the period before an individual hits the coverage gap and gap refers to the period
during the coverage gap.

Determination of benefit phases
In order to assess whether a Medicare health plan member enters the coverage
gap, total costs and true out-of-pocket (TrOOP) costs must be calculated. Total costs
represent those associated with filling a prescription drug and include the amount the
health plan pays and the amount a health plan member pays (co-pay or member
responsibility amount) after filling a prescription drug.
True out-of-pocket costs, on the other hand, include only costs incurred by the
health plan member. TrOOP costs are the prescription drug costs that count toward the
annual out- of-pocket threshold that health plan members must reach before the
catastrophic drug benefit phase begins (Center for Medicaid and Medicare Services,
2014). Payment that counts toward TrOOP includes the amount a person pays for covered
prescriptions before the plan begins to pay (the deductible phase), the amount a person
pays for each covered prescription after the plan begins to pay (copayments or
coinsurance during initial coverage period) and payments made for a covered prescription
while in the coverage gap.
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Payments for TrOOP eligible costs can be made by any of the following (Center
for Medicaid and Medicare Services, 2014):
•

The person enrolled in a Medicare drug plan (including payments from his
or her Medical Savings Account [MSA], Health Savings Account [HSA],
or Flexible Spending Account [FSA])

•

Family of the health plan member or friends

•

Qualified State Pharmacy Assistance Programs (SPAPs)

•

Medicare’s Extra Help (low-income subsidy)

•

Most charities (unless they’re established, run, or controlled by the
person’s current or former employer or union or by a drug manufacturer’s
Patient Assistance Program operating outside Part D)	
  

•

Drug manufacturers providing discounts under the Medicare coverage gap
discount program

•

Indian Health Service (IHS)

•

AIDS Drug Assistance Programs (ADAPs)

The drugs must be on the plan’s formulary or treated as “on formulary” due to a coverage
determination, exceptions process or appeal. The drugs must be purchased at an innetwork pharmacy or in accordance with the health plan’s out of network policy.
Payments that do not count toward TrOOP costs include the drug cost share paid
by the plan, monthly plan premiums paid by the health plan member, drugs purchased
outside the U.S and its territories, drugs not covered by the plan, drugs that are excluded
from the definition of Part D drug (even in cases where the plan chooses to cover them)
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and over-the-counter (OTC) drugs (even in cases where the plan requires them for step
therapy) (Center for Medicaid and Medicare Services, 2014).
Payments do not count toward TrOOP if made by the following (Center for
Medicaid and Medicare Services, 2014):
§

Group health plans such as the Federal Employees Health Benefit Program
(FEHBP) or employer or union retiree coverage

§

Government-funded health programs such as Medicaid, TRICARE, Workers’
Compensation, the Department of Veterans Affairs (VA), Federally Qualified
Health Centers (FQHCs), Rural Health Clinics (RHCs), the Children’s Health
Insurance Program (CHIP), and black lung benefits

§

Other third-party groups with a legal obligation to pay for the person’s drug
costs

§

Patient Assistance Programs (PAPs) operating outside the Part D benefit

§

Other types of insurance

For health plan members enrolled in standard Part D plans, the table below was
used to determine benefit phases for the respective plan year.
Table 4. 2009-2014 Medicare Part D Standard Benefit Model Plan Parameters, including
True Out-Of-Pocket (TrOOP) amounts (Q1Group)
Year
Initial
Total Drug Cost for TrOOP for
Deductible
Coverage Gap
Catastrophic
Entry
Coverage
2009
$295
$2,700
$4,350
2010
$310
$2,830
$4,550
2011
$310
$2,840
$4,550
2012
$320
$2,930
$4,700
2013
$325
$2,970
$4,750
2014
$310
$2,850
$4,550
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The following methodology was used to assess whether a health plan member hit
the coverage gap or moved on to catastrophic coverage:
1) Total drug costs (drug cost + dispensing fee) were calculated for each health
plan member. The next step involved determining health plan members who had total
costs less than the total drug cost for coverage gap entry for the plan year and plan
members who had total costs less than the threshold. For 2009, this amount was $2,700.
Health plan members who had total costs less than $2,700 represented those who
remained in the initial coverage limit. Health plan members who had total costs greater
than $2,700 were those who hit the coverage gap.
2) For health plan members with total drug costs greater than $2,700, their TrOOP
costs were calculated. For plan year 2009, health plan members who incurred TrOOP
costs less than or equal to $4,350 and health plan members who incurred TrOOP costs
greater than $4,350 were identified. Health plan members with TrOOP costs less than or
equal to $4,350 represented those who remained in the coverage gap through the entire
year. Health plan members with TrOOP costs greater than $4,350 represented those who
were covered under the catastrophic coverage limit.

b) Dependent Variable or Outcome Measure
Medication adherence is the primary outcome measure of this study. Adherence
was calculated using portion of days covered (PDC), which is the method endorsed by
the Pharmacy Quality Alliance (PQA) (Nau). PDC is also the medication adherence
measure used by CMS to assign stars to health plans from which quality bonus payments
are calculated (Green, 2013). Based on numerous studies of the relationship of
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medication adherence and healthcare outcomes, PQA selected 0.8 (or 80 percent) as the
threshold above which the patient can be considered to be adherent for most classes of
chronic medications, including diabetic medications.

Steps and Assumptions considered for medication adherence calculation
The following steps and assumptions were considered to calculate medication
adherence:
1) An adherence value was calculated for each Medicare health plan member. The pregap PDC reflects adherence before a health plan member hits the coverage gap and the
gap-PDC reflects adherence during the coverage gap.
2) The day a health plan member’s total costs are equal to the coverage gap limit for that
year, was considered as the day a health plan member hits the coverage gap. All
prescriptions filled on the day a health plan member hits the coverage gap were
considered as prescriptions filled after hitting the coverage gap.
3) Medication adherence was calculated by using the health plan member’s January index
fill as the start date and December 31st as the end date.
4) If a health plan member’s days supply for their last fill was greater than the number of
days in the calendar year, then the days supply was truncated to reflect the number of
days left in the calendar year.
5) The variable days supply associated with dosage forms such as an injectable (e.g.
insulin) may result in incorrect estimates. Thus, as is frequently done in studies assessing
medication adherence, only oral dosage and fixed dose injectable forms were considered
for the purposes of medication adherence calculations.
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6) Medication adherence was calculated per drug class and not for specific drugs. As long
as a health plan member filled any medication within a drug class, the health plan
member was considered adherent.
7) It is assumed that a health plan member is prescribed only one medication per drug
class.

Portion of Days Covered (PDC) Calculation
The PDC measures the quantity of days a health plan member has a drug available
during the study interval by assigning a simple binary measure indicating the presence or
absence of the study drug for each day in the study period. Therefore, drug oversupplies
from early refills are not included in PDC calculations. The PDC is a ratio with a range of
0-1, with a higher number indicating higher adherence. A ratio of greater than 1.0 is not
possible, as the PDC is capped at 1.0 (Martin et al., 2009).
PDC = Total Days Medication is Available x 100
Total Number of Days Evaluated
The numerator in the PDC was calculated by utilizing claims data to determine if
a health plan member had medication coverage for each day in the study period. Dummy
variables with values of 0 or 1 were assigned to each day in the period. If a health plan
member had prescription drug coverage for a particular day they were assigned a value of
1. If they did not have prescription drug coverage for a particular day they were assigned
a value of 0. The sum of all days that a health plan member had medication coverage
provided the numerator for the PDC calculation. This approach is common when
measuring PDC for a therapeutic class, where health plan members are concurrently
prescribed more than one medication from within the same therapeutic class. It is also
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useful to account for drug switches, addition of drugs within a class and early refills.
Counting medications per day prevents over-estimation of adherence values.

Propensity Score Matching
Propensity score matching (PSM), first published by Paul Rosenbaum and Donald
Rubin in 1983, is a statistical matching technique that attempts to estimate the effect of a
treatment, policy or other intervention by accounting for the covariates that predict
receiving the treatment (Rosenbaum & Rubin, 1983). PSM involves forming matched
sets of treated and untreated subjects that share a similar value of the propensity score
(Austin, 2014). PSM attempts to reduce the bias due to confounding variables that could
be found in an estimate of the treatment effect obtained from simply comparing outcomes
among health plan members that received the treatment versus those that did not.
Matching attempts to mimic randomization by creating a sample of health plan members
that received the treatment that is comparable on all observed covariates to a sample of
health plan members that did not receive the treatment.
Propensity score matching utilized the traditional framework of matching two
groups to make them comparable but rather than match individually on multiple
variables, it matches them on a single indicator, the propensity score (Rosenbaum &
Rubin, 1983). When matching, controls from the low-income subsidy group were
selected who had similar propensity scores to those in the treatment group (those with a
coverage gap). The goal was a dataset of treatments and controls with similar
characteristics on all key variables that were used to define the propensity scores. The
propensity score is defined as the probability of being in the treatment group given the
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individual's level on the covariates included in the model (Rosenbaum & Rubin, 1983).
The propensity score was estimated using a logistic regression model. Logistic regression
makes no assumptions about the distributions of the covariates on the dichotomous
outcome (D'Agostino 1998). A single propensity score was estimated for every individual
in the study, both treatments and controls. This propensity score was then used to adjust
for the differences between the two groups on the observed covariates in the study. Thus,
the propensity score allows researchers to control for a large number of background
covariates simultaneously based on a single number (Rosenbaum & Rubin, 1983).
Based on Andersen's Behavioral Model of Health Services Use as described in
depth in chapter 2 and a review of the literature citing factors affecting medication
adherence, the following variables were used as covariates: age, gender and race
(Andersen, 1995; Zhang et al., 2013). Data on age, gender and race were readily available
from the data set.
A random id variable was introduced to allow a different ordering of data for the
match in order to approximate a randomized control trial. The matching method used was
the Nearest Neighbor Without Replacement Caliper Match. “Nearest Neighbor” signifies
treatments are being assigned to controls based on the first pairing that meets the
matching criteria. “Without Replacement” denotes controls are removed once matched to
a case so the controls cannot be matched to more than one case. “Caliper” refers to the
number of decimals used in matching and acts as a constraint to allow the matching
algorithm to be more or less restrictive. Medical literature recommends that, in most
situations, nearest neighbor caliper matching without replacement (random order or
closest distance) be used when forming pairs of treated and untreated subjects with
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similar values of the propensity score (Austin, 2014). This approach tended to result in
estimates with minimal bias compared with other algorithms across a wide range of
scenarios.

Data analyses required to address objectives:
1) To evaluate diabetes medication adherence of health plan members before they reach
the coverage gap and then while they are in the coverage gap.
Data: Pharmacy claims data for Medicare health plan members with no
prescription drug coverage during the coverage gap.
Analysis: Statistical significance was assessed at α = 0.05 using a paired t-test to
compare the pre-coverage and coverage gap mean PDC
Table 5. Proposed data layout to evaluate Objective 1
Year

Pre Coverage Gap
mean PDC

Coverage Gap
mean PDC

Statistical
Significance

2009
2010
2011
2012
2013
2014
2) To compare diabetes medication adherence between two similar groups with differing
benefit structures, one group with a gap in coverage as opposed to a group with no
benefit changes within the year.
Data: Pharmacy claims data for Medicare health plan members enrolled in plans
with no gap in coverage and Medicare health plan members without any prescription
drug coverage during the coverage gap.
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Analysis: Statistical significance was assessed at α = 0.05 using a paired t-test to
compare the control and treatment mean PDC by year.

Table 6. Proposed data layout to evaluate Objective 2
Year

Control Group
mean PDC

Treatment Group
mean PDC

Statistical
Significance

2009
2010
2011
2012
2013
2014
3) To examine diabetes medication adherence trend over multiple years as the coverage
gap is closed.
Data: Pharmacy claims data for Medicare health plan members enrolled in plans
with no gap in coverage and Medicare health plan members without any prescription
drug coverage during the coverage gap.
Analysis: Statistical significance was assessed at α = 0.05 using a paired t-test to
compare 2009 mean PDC to each subsequent year for both control and treatment groups.

Table 7. Proposed data layout to evaluate Objective 3
Control Group
Statistical
Significance

Treatment
Group
Statistical
Significance

2009 vs 2010
2009 vs 2011
2009 vs 2012
2009 vs 2013
2009 vs 2014
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Confidentiality
The University of Louisville Institutional Review Board (IRB) evaluated and
granted approval for this study after an expedited review. A copy of the approval letter is
included in Appendix A.

Summary
This study focuses on Medicare health plan members utilizing diabetic
medications from a mail order pharmacy. A retrospective, pre-post cohort analysis with
control group study design was used to determine the effect of the Medicare Part D
coverage gap on diabetic medication adherence. Medicare health plan members who met
the study inclusion criteria were selected from the health plan’s covered 7 million lives.
For members in the study group, total costs and TrOOP were calculated to determine
whether they entered the coverage gap. Members of the comparison group had no gap in
coverage during the respective plan year.
Pre-coverage gap and within coverage gap analysis was conducted for the study
group. Medication adherence was calculated using PDC, which is the method endorsed
by the PQA and used by CMS to assign health plan star ratings. Propensity score
matching was used to obtain balanced control and treatment groups based on covariates
of age, race and gender. The PSM models were analyzed for goodness of fit. Mean
adherence was analyzed between the groups along with the mean medication adherence
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trend over multiple years as the coverage gap is closed due to the ACA. The results
obtained from the data analyses are presented in Chapter 4.
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CHAPTER 4
RESULTS
	
  
This chapter begins with a discussion of the study population and specifics
regarding the inclusion/exclusion process. Next, details of those reaching the coverage
gap are presented. In the following section, results of the descriptive analyses of precoverage gap and within coverage gap diabetic medication adherence are provided. Then,
propensity score matching models are delivered and goodness of fit test results presented.
Finally, diabetic medication adherence results from the propensity score matched groups
are offered and compared.

Study Population
The study sample was selected from Humana Medicare health plan members
enrolled in a Medicare Advantage (MAPD) prescription drug plan or Part D plan (PDP)
during the study years of interest. The health plan members were divided into two cohorts
by brand or generic diabetic medication utilization. Generic formulations of the study
drugs were identified using a generic product indicator (GPI) variable for each drug in
each year of the database.
The following criteria were utilized to determine inclusion/exclusion of the
treatment group:
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1) At least one prescription claim for a medication of interest at Humana’s mail
order pharmacy during the month of January in plan years 2009, 2010, 2011,
2012, 2013 or 2014
2) Aged 18 to 89 years at the beginning of the plan year
3) Exclusion of members eligible for Low Income Subsidy (LIS) benefit (these
members were utilized for the control group if they met eligibility criteria in the
next step)
4) 12 months continuous enrollment in a plan year
5) Reached the Medicare coverage gap spending limits between April 1st and
September 30th during the respective plan year
Figure 6 presents the study sample and health plan members using brand diabetic
medications that reached the coverage gap. Figure 7 presents the study sample and health
plan members using generic diabetic medications that reached the coverage gap. There is
a significant decrease in study population during the last step because a relatively small
percent (12-14 percent) of overall Part D health plan members have spending to reach the
coverage gap.
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Coverage gap
Of the health plan members who met the study inclusion and exclusion criteria, a
greater percentage of brand diabetic medication utilizers entered the coverage gap as
compared with those utilizing generic medication. As shown in Figure 8, the percentage
of health plan members reaching the coverage gap increased steadily each year for the
brand cohort. The generic cohort exhibited a slight increase year over year with the
exception of years 2012-2013.
Figure 8. Percent of eligible study participants who reach the coverage gap by cohort and
year
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10.00%$
5.00%$
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1.56%$

1.55%$

1.47%$

1.98%$

Coverage gap month
The percent of health plan members who entered the coverage gap between April
and September, by cohort are shown in Figures 9 and 10. Of those members who entered
the coverage gap in this study, the largest percentage moved into the coverage gap in
September, regardless of cohort.
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Figure 9. Percent of health plan members utilizing brand diabetic medications who reach
the coverage gap between April and September, by month
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Figure 10. Percent of health plan members utilizing generic diabetic medications who
reach the coverage gap between April and September, by month
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It is possible for health plan members to fall into both cohorts if they are using
both brand and generic medications. A breakout of these groups is provided in Table 8.
The percentage of health plan members using only generic medications increased while
the groups using only brand medications and both medications declined over the study
period.
Table 8. Percent of total health plan members utilizing brand only, generic only or both
2009
2010
2011
2012
2013
2014
Brand only
41%
34%
35%
33%
35%
36%
Generic only
9%
8%
11%
21%
27%
26%
Both generic
and brand
50%
57%
53%
46%
38%
39%
Figures 11-13 present the percent of health plan members who hit the gap by month
based on whether they used brand, generic or both medications.
Figure 11. Percent of health plan members utilizing only brand diabetic medications who
reach the coverage gap between April and September, by month
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Figure 12. Percent of health plan members utilizing only generic diabetic medications
who reach the coverage gap between April and September, by month

Figure 13. Percent of health plan members utilizing both brand and generic diabetic
medications who reach the coverage gap between April and September, by month

	
  

52	
  

Descriptive analyses of pre-coverage gap and within coverage gap medication
adherence
Mean medication adherence by cohort for health plan members before they
reached the coverage gap and then while they were in the coverage gap is displayed in
Tables 9 and 10. As shown in the tables, overall pre-coverage gap medication adherence
was higher than medication adherence while in the coverage gap. Paired t-tests indicate
significant differences in the brand cohort for all years and the generic cohort for years
2010-2012.
Table 9. Univariate analysis comparing medication adherence pre-coverage gap and
within the coverage gap for the brand cohort
Brand
Pre-cov. gap Within cov.
Paired T test
PDC
gap PDC
2009
2010
2011
2012
2013
2014

N
260
387
943
1084
1150
2002

Mean
0.901
0.909
0.909
0.883
0.877
0.858

SD
0.097
0.080
0.078
0.100
0.101
0.116

Mean
0.861
0.868
0.857
0.828
0.835
0.828

SD
0.184
0.168
0.159
0.197
0.190
0.195

Mean
0.040
0.041
0.051
0.055
0.042
0.030

SD
0.207
0.185
0.178
0.218
0.206
0.216

DF
259
296
942
1083
1149
2001

t
3.15
4.33
8.84
8.32
6.96
6.30

p
0.0018
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

Table 10. Univariate analysis comparing medication adherence pre-coverage gap and
within the coverage gap for the generic cohort
Generic
Pre-cov. gap Within cov.
Paired T test
PDC
gap PDC
2009
2010
2011
2012
2013
2014

N
170
281
677
916
1026
1727

Mean
0.870
0.883
0.882
0.873
0.874
0.876

SD
0.111
0.127
0.119
0.117
0.125
0.118

Mean
0.845
0.822
0.847
0.829
0.865
0.867

SD
0.211
0.237
0.211
0.231
0.223
0.222
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Mean
0.025
0.061
0.035
0.043
0.009
0.009

SD
0.194
0.225
0.209
0.236
0.210
0.215

DF
169
280
676
915
1025
1726

t
1.68
4.52
4.30
5.55
1.38
1.74

p
0.0940
<0.0001
<0.0001
<0.0001
0.1671
0.0823

As previously noted, PQA selected 0.8 (or 80 percent) as the threshold above
which the patient can be considered to be adherent for most classes of chronic
medications. The percent of health plan members in each cohort that were adherent with
a PDC > 80% during the pre-coverage gap phase and during the coverage gap phase are
presented in Figures 14 and 15. In each cohort, the percentage of adherent members was
greater in the pre-coverage gap period versus the gap period (consistent p-value < 0.05).
The health plan member cost share amount for the index fill in January, as well as
the days spent pre-gap and within the coverage gap are presented in Tables 11 and 12. In
general, the findings reflect an increase in member cost share for brand diabetic
medications year over year.
Figure 14. Percent of health plan members utilizing brand diabetic medications that were
adherent with a PDC > 80%
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Figure 15. Percent of health plan members utilizing generic diabetic medications that
were adherent with a PDC > 80%
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Table 11. Index fill cost share, days spent in pre-coverage gap and coverage gap for
health plan members using brand diabetic medications
2009
2010
2011
2012
2013
2014
n
260
387
943
1084
1150
2002
Index Fill
40.36
42.73
45.96
49.38
49.10
58.80
Health Plan
Member Cost
Share
Days Pre-Gap
211.7
214.4
219.2
210.5
224.9
213.8
Days Gap
153.3
150.6
145.8
155.5
140.1
151.2
All numbers reported as mean
Table 12. Index fill cost share, days spent in pre-coverage gap and coverage gap for
health plan members using generic diabetic medications
2009
2010
2011
2012
2013
2014
n
170
281
677
916
1026
1727
Index Fill
4.25
1.53
1.90
1.79
9.65
4.76
Health Plan
Member Cost
Share
Days Pre-Gap
216.7
217.8
222.0
207.4
218.1
214.3
Days Gap
148.3
147.2
143.0
158.6
146.8
150.7
All numbers reported as mean
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Propensity score matching
Objective 2 required the used of a control group. Medicare Part D health plan
members eligible for a low-income subsidy (LIS) were chosen because they do not incur
the full cost of medications in the Part D coverage gap. The following criteria were
utilized to determine inclusion/exclusion of the control group:
1) At least one prescription claim for a medication of interest at Humana’s mail
order pharmacy during the month of January in plan years 2009, 2010, 2011,
2012, 2013 or 2014
2) Aged 18 to 89 years at the beginning of the plan year
3) 12 months continuous enrollment in a plan year
4) Reached the Medicare coverage gap spending limits between April 1st and
September 30th during the respective plan year
The propensity score for matching was obtained utilizing a logistic regression
analysis where the dependent variable was a LIS indicator. Excluded from the matched
sample were untreated subjects that could not be matched to a treated subject with a
propensity score within the caliper range of 0.001. The caliper refers to the number of
decimals allowed for a treatment to be matched to a control based on propensity score.
Smaller calipers result in stricter matches. A “greedy”, nearest-neighbor matching
algorithm was utilized to form pairs of treated and untreated subjects. Austin advises
“greedy, nearest neighbor matching within specified caliper widths may not result in all
treated subjects being matched to an untreated subject, because for some treated subjects,
there may not be any untreated subjects who are unmatched and whose propensity score
lies within the specified caliper distance of that of the treated subject (Austin, 2014).”
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Prior to analyzing any results from a propensity- score matched model, it is
necessary to evaluate the model’s goodness of fit. Ho et al. suggest the propensity-score
model is adequate when the distribution of measured baseline covariates is similar
between treated and untreated subjects (D. Ho, Imai, King, & Stuart, 2007). Therefore,
the appropriateness of the model is assessed by examining the degree to which matching
on the estimated propensity score has resulted in a matched sample where the distribution
of measured baseline covariates is similar between treated and untreated subjects (Austin,
2014).
The method used to assess the model’s fit in this study was standardized
difference. The standardized difference compares the difference in means in units of the
pooled standard deviation (Austin, 2014). The standardized difference is not influenced
by sample size unlike t-tests and other statistical tests of hypothesis. Therefore, the
standard difference can be useful to evaluate balance in measured variables between
treated and untreated subjects in the matched sample with that in the unmatched sample.
Rosenbaum and Rubin first published their use of the standardized difference to assess
the comparability of treated and untreated subjects in matched samples (Rosenbaum &
Rubin, 1985). Since then, several authors have used this approach in the clinical literature
(Austin, 2008a, 2008c; Normand et al., 2001)
Absolute standardized differences comparing baseline covariates between treated
and untreated subjects in the unmatched and matched samples are reported in Tables 13 24. In the unmatched sample, the largest absolute standardized differences were observed
in the age difference of the groups with the control group being younger than the
treatment group (0.200 – 0.759). In general, the propensity score resulted in a matched

57	
  

sample in which the means and percentages of baseline covariates were relatively similar
between treated and untreated subjects. For example, the ability of PSM to equalize
variables is illustrated in Table 13. The unmatched control group had a mean age of 64.7
years, a little over half were female and less than a third of the members were white. The
matched sample equalized the variability so both samples were 69.1 years in mean age, a
little over half were female and race exhibited a far less pronounced gap. While PSM
attempts to reduce the difference among the groups, it cannot eliminate them completely.
For example, as shown in Table 19, some marked differences remain in the matched
groups for mean age (69.7 vs. 72.0) and gender (53.5% vs. 77.0%).
Table 13. Comparison of baseline statistics for unmatched and matched health plan
members for brand diabetic medication cohort, 2009
Original Unmatched Sample
Propensity-score Matched Sample
Var.
Control
Treatment Std.
Control
Treatment Std.	
  
LI: Yes
LI: No
Diff. LI: Yes
LI: No
Diff.	
  
(N = 45)
(N = 260)
(N = 27)
(N = 27)
Age
64.7 ± 9.8
70.7 ± 6.1
0.726 69.1 ± 6.0
69.1 ± 5.9
0.006
Female 25 (55.6%)
91 (35.0%)
0.422 16 (59.2%)
16 (59.2%)
0.000
White
70 (26.9%)
188 (72.3%) 0.027 22 (81.5%)
21 (77.8%)
0.092
Continuous variables are reported as mean ± standard deviation.
Dichotomous variables are reported as N (percent).
	
  
Table 14. Comparison of baseline statistics for unmatched and matched health plan
members for generic diabetic medication cohort, 2009
Original Unmatched Sample
Propensity-score Matched Sample
Var.
Control
Treatment Std.
Control
Treatment Std.	
  
LI: Yes
LI: No
Diff. LI: Yes
LI: No
Diff.	
  
(N = 29)
(N = 170)
(N = 18)
(N = 18)
Age
65.4 ± 10.3
71.0 ± 5.7
0.681 70.5 ± 5.3
70.6 ± 5.5
0.010
Female 12 (41.4%)
63 (37.1%)
0.089 9 (50.0%)
9 (50.0%)
0.000
White
21 (72.4%)
125 (73.5%) 0.035 14 (77.8%)
16 (88.9%)
0.302
Continuous variables are reported as mean ± standard deviation.
Dichotomous variables are reported as N (percent).
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Table 15. Comparison of baseline statistics for unmatched and matched health plan
members for brand diabetic medication cohort, 2010
Original Unmatched Sample
Propensity-score Matched Sample
Var.
Control
Treatment Std.
Control
Treatment Std.	
  
LI: Yes
LI: No
Diff. LI: Yes
LI: No
Diff.	
  
(N = 79)
(N = 387)
(N = 58)
(N = 58)
Age
68.9 ± 9.7
70.7 ± 5.7
0.238 70.6 ± 7.9
71.1 ± 5.8
0.074
Female 47 (59.5%)
145 (37.5%) 0.452 33 (56.9%)
33 (56.9%)
0.000
White
55 (69.6%)
312 (80.6%) 0.257 45 (75.6%)
42 (72.4%)
0.120
Continuous variables are reported as mean ± standard deviation.
Dichotomous variables are reported as N (percent).
Table 16. Comparison of baseline statistics for unmatched and matched health plan
members for generic diabetic medication cohort, 2010
Original Unmatched Sample
Propensity-score Matched Sample
Var.
Control
Treatment Std.
Control
Treatment Std.	
  
LI: Yes
LI: No
Diff. LI: Yes
LI: No
Diff.	
  
(N = 53)
(N = 281)
(N = 39)
(N = 39)
Age
69.2 ± 7.9
70.5 ± 5.4
0.200 70.9 ± 5.3
70.7 ± 5.4
0.043
Female 35 (66.0%)
105 (37.3%) 0.599 24 (30.8%)
24 (30.8%)
0.000
White
41 (77.4%)
226 (80.4%) 0.075 31 (79.5%)
32 (82.1%)
0.065
Continuous variables are reported as mean ± standard deviation.
Dichotomous variables are reported as N (percent).
Table 17. Comparison of baseline statistics for unmatched and matched health plan
members for brand diabetic medication cohort, 2011
Original Unmatched Sample
Propensity-score Matched Sample
Var.
Control
Treatment Std.
Control
Treatment Std.	
  
LI: Yes
LI: No
Diff. LI: Yes
LI: No
Diff.	
  
(N = 136)
(N = 943)
(N = 101)
(N = 101)
Age
66.8 ± 9.4
71.0 ± 5.9
0.540 69.4 ± 7.4
69.7 ± 7.8
0.040
Female 81 (59.6%)
344 (36.5%) 0.475 61 (60.4%)
65 (64.4%)
0.082
White
103 (75.7%)
844 (89.5%) 0.369 85 (84.2%)
85 (84.2%)
0.000
Continuous variables are reported as mean ± standard deviation.
Dichotomous variables are reported as N (percent).
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Table 18. Comparison of baseline statistics for unmatched and matched health plan
members for generic diabetic medication cohort, 2011
Original Unmatched Sample
Propensity-score Matched Sample
Var.
Control
Treatment Std.
Control
Treatment Std.	
  
LI: Yes
LI: No
Diff. LI: Yes
LI: No
Diff.	
  
(N = 111)
(N = 677)
(N = 81)
(N = 81)
Age
66.2 ± 9.9
70.8 ± 5.8
0.565 69.3 ± 7.5
70.7 ± 7.0
0.186
Female 64 (57.7%)
258 (38.1%) 0.399 46 (56.8%)
56 (69.1%)
0.258
White
86 (77.5%)
603 (89.1%) 0.314 70 (86.4%)
60 (74.1%)
0.314
Continuous variables are reported as mean ± standard deviation.
Dichotomous variables are reported as N (percent).
Table 19. Comparison of baseline statistics for unmatched and matched health plan
members for brand diabetic medication cohort, 2012
Original Unmatched Sample
Propensity-score Matched Sample
Var.
Control
Treatment
Std.
Control
Treatment Std.	
  
LI: Yes
LI: No
Diff. LI: Yes
LI: No
Diff.	
  
(N = 344)
(N = 1084)
(N = 217)
(N = 217)
Age
65.1 ± 10.3
71.1 ± 5.8
0.717 69.7 ± 7.2
72.0 ± 7.9
0.307
Female 202 (58.7%)
360 (33.2%)
0.530 116 (53.5%) 167 (77.0%) 0.509
White
274 (79.7%)
1016 (93.7%) 0.424 198 (91.2%) 200 (92.2%) 0.033
Continuous variables are reported as mean ± standard deviation.
Dichotomous variables are reported as N (percent).
	
  
Table 20. Comparison of baseline statistics for unmatched and matched health plan
members for generic diabetic medication cohort, 2012
Original Unmatched Sample
Propensity-score Matched Sample
Var.
Control
Treatment
Std.
Control
Treatment Std.	
  
LI: Yes
LI: No
Diff. LI: Yes
LI: No
Diff.	
  
(N = 291)
(N = 916)
(N = 196)
(N = 196)
Age
64.9 ± 10.3
70.6 ± 5.7
0.680 68.6 ± 7.5
68.6 ± 7.3
0.002
Female 176 (60.5%)
314 (34.3%)
0.544 115 (58.7%) 114 (58.2%) 0.010
White
228 (74.4%)
846 (92.4%)
0.404 175 (89.3%) 174 (88.8%) 0.016
Continuous variables are reported as mean ± standard deviation.
Dichotomous variables are reported as N (percent).
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Table 21. Comparison of baseline statistics for unmatched and matched health plan
members for brand diabetic medication cohort, 2013
Original Unmatched Sample
Propensity-score Matched Sample
Var.
Control
Treatment
Std.
Control
Treatment Std.	
  
LI: Yes
LI: No
Diff. LI: Yes
LI: No
Diff.	
  
(N = 392)
(N = 1150)
(N = 275)
(N = 275)
Age
69.2 ± 10.6
71.2 ± 5.8
0.702 68.8 ± 8.3
71.7 ± 6.6
0.385
Female 269 (68.6%) 469 (40.8%)
0.583 169 (61.5%) 241 (87.6%) 0.630
White
317 (80.9%) 1064 (92.5%) 0.348 244 (88.7%) 243 (88.4%) 0.011
Continuous variables are reported as mean ± standard deviation.
Dichotomous variables are reported as N (percent).
	
  
Table 22. Comparison of baseline statistics for unmatched and matched health plan
members for generic diabetic medication cohort, 2013
Original Unmatched Sample
Propensity-score Matched Sample
Var.
Control
Treatment
Std.
Control
Treatment Std.	
  
LI: Yes
LI: No
Diff. LI: Yes
LI: No
Diff.	
  
(N = 357)
(N = 1026)
(N = 221)
(N = 221)
Age
64.6 ± 10.2
70.5 ± 5.8
0.712 69.1 ± 6.8
69.3 ± 7.1
0.029
Female 248 (69.5%)
416 (40.6%)
0.608 151 (68.3%) 154 (70.1%) 0.039
White
284 (79.6%)
939 (91.5%)
0.345 200 (90.5%) 200 (90.5%) 0.000
Continuous variables are reported as mean ± standard deviation.
Dichotomous variables are reported as N (percent).
Table 23. Comparison of baseline statistics for unmatched and matched health plan
members for brand diabetic medication cohort, 2014
Original Unmatched Sample
Propensity-score Matched Sample
Var.
Control
Treatment
Std.
Control
Treatment Std.	
  
LI: Yes
LI: No
Diff. LI: Yes
LI: No
Diff.	
  
(N = 665)
(N = 2002)
(N = 460)
(N = 460)
Age
65.2 ± 10.3
71.2 ± 6.2
0.701 69.4 ± 7.3
69.5 ± 7.6
0.019
Female 431 (64.8%)
839 (41.9%)
0.472 293 (63.7%) 307 (66.7%) 0.064
White
505 (75.9%)
1836 (91.7%) 0.438 380 (82.6%) 378 (82.2%) 0.011
Continuous variables are reported as mean ± standard deviation.
Dichotomous variables are reported as N (percent).
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Table 24. Comparison of baseline statistics for unmatched and matched health plan
members for generic diabetic medication cohort, 2014
Original Unmatched Sample
Propensity-score Matched Sample
Var.
Control
Treatment
Std.
Control
Treatment
Std.	
  
LI: Yes
LI: No
Diff.
LI: Yes
LI: No
Diff.	
  
(N = 589)
(N = 1727)
(N = 408)
(N = 408)
Age
64.6 ± 10.1 70.9 ±6.1
0.759
68.3 ± 7.5
68.5 ± 7.5
0.029
Female 380 (64.5%) 718 (41.6%)
0.472
264 (64.7%) 270 (66.2%) 0.030
White
458 (77.8%) 1587 (91.9%) 0.402
348 (85.3%) 340 (83.3%) 0.054
Continuous variables are reported as mean ± standard deviation.
Dichotomous variables are reported as N (percent).
The C-statistic, which is an indicator for concordance, is also useful in evaluating
the goodness of fit of logistic regression models. The C-Statistic offers values ranging
from 0.5 to 1.0. A value of 0.5 indicates that the model is no better than chance at making
a prediction of membership in a group and a value of 1.0 indicates that the model
perfectly identifies those within a group and those not. Models are typically considered
reasonable when the C-statistic is higher than 0.7 and strong when C exceeds 0.8
(Hosmer & Lemeshow, 1989). All C-statistics were above 0.7 and are provided in Table
25.
Table 25. C-statistics for logistic regression models by year, medication cohort
Year
Brand diabetic
Generic diabetic
medication cohort medication cohort
2009
0.773
0.700
2010
0.701
0.706
2011
0.713
0.705
2012
0.761
0.759
2013
0.761
0.761
2014
0.755
0.765
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Descriptive analyses of propensity score matched control and treatment groups
Mean medication adherence by cohort for propensity score matched health plan
members is presented in Tables 26 - 27. The control group represents those health plan
members with no gap in coverage during the plan year and the treatment group represents
those health plan members who reached the Part D coverage gap. As shown in the tables,
the control group exhibited higher medication adherence. T-tests indicate significant
differences in the brand cohort for years 2011-2014 and the generic cohort for years
2013-2014.
Table 26. Univariate analysis comparing medication adherence of the control and
treatment groups for the brand cohort
Brand
Control
Treatment
T test
Group
Group
Annual PDC Annual PDC
N
Mean SD
Mean SD
Mean SD
DF
t
p
2009 27 0.928 0.070 0.884 0.104 0.044 0.089 52
1.83
0.0730
2010 58 0.927 0.093 0.901 0.082 0.026 0.088 114
1.62
0.1091
2011 101 0.919 0.090 0.879 0.095 0.041 0.013 200
3.12
0.0021
2012 217 0.919 0.082 0.874 0.115 0.046 0.100 432
4.74
<0.0001
2013 275 0.910 0.093 0.857 0.111 0.053 0.102 548
6.12
<0.0001
2014 460 0.913 0.087 0.839 0.121 0.074 0.106 918
10.65
<0.0001
Table 27. Univariate analysis comparing medication adherence of the control and
treatment groups for the generic cohort
Generic
Control
Treatment
T test
Group
Group
Annual PDC Annual PDC
N
Mean SD
Mean SD
Mean SD
DF
t
p
2009 18
0.899 0.121 0.899 0.084 0.000 0.106 30
0.01 0.9928
2010 39
0.882 0.170 0.849 0.181 0.034 0.175 76
0.85 0.4000
2011 81
0.876 0.165 0.883 0.108 0.007 0.140 138 0.34 0.7368
2012 196
0.889 0.146 0.867 0.140 0.022 0.143 390 1.51 0.1318
2013 221
0.899 0.138 0.871 0.135 0.028 0.137 435 2.16 0.0311
2014 408
0.903 0.136 0.874 0.127 0.029 0.132 808 3.17 0.0016
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Diabetic medication adherence across plan years
Medication adherence across plan years is presented in Figures 16-19. Plan year
2009 is used as a reference and statistical significance is denoted with an asterisk. The
only statistically significant difference was seen in the decline in brand diabetic
medication adherence for the treatment group from 2009 to 2014
Figure 16. Control group medication adherence across plan years for the brand cohort
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Figure 17. Control group medication adherence across plan years for the generic cohort

Figure 18. Treatment group medication adherence across plan years for the brand cohort
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Figure 19. Treatment group medication adherence across plan years for the generic
cohort

Summary
The percent of eligible study participants who reached the coverage gap more
than doubled between 2009 and 2014. Overall pre-coverage gap medication adherence
was higher than medication adherence in the coverage gap. Significant differences were
noted in the brand cohort for all years and the generic cohort for years 2010-2012. A
comparison of medication adherence between the control and treatment group showed
statistically significant differences for almost all years in the brand cohort and later year s
in the generic cohort. However, medication adherence across plan years showed
statistically significant differences for one year in the treatment brand cohort only.
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CHAPTER 5
DISCUSSION
This chapter begins with a discussion of the study results with regard to the
research objectives. In addition to the results, a discussion of strengths, limitations,
findings and recommendations for future research are offered.

Coverage Gap
As shown in Figure 8, the percent of eligible study participants in the brand
cohort who entered the coverage gap ranged from 4.62 percent (2009) to 24.01 percent
(2014). In the generic cohort, the percent of eligible study participants who entered the
coverage gap ranged from 0.82 percent (2009) to 1.98 percent (2014). A study conducted
by Kaiser Family Foundation reported that 26 percent of non-LIS Part D enrollees who
filled one or more prescriptions in 2007 reached the coverage gap (Hoadley, Hargrave,
Cubanski, & Neuman, 2008). Each year the Medicare Payment Commission (MEDPAC)
publishes the percent of Part D enrollees that reach the coverage gap in The Medicare
Payment Policy Report to the Congress. Data available for non-LIS Part D enrollees from
2009 through 2012 is displayed in Figure 20. Since 2007, the proportion of Part D nonLIS enrollees reaching the gap has declined, likely due to the increased availability of
generic medications for many chronic conditions (Hoadley et al., 2011). However, the
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absolute number of people reaching the gap has declined less than the proportion because
of an increase in the number of Part D enrollees as shown in Table 28.

Figure 20. Percent of non-LIS Part D enrollees who entered the coverage gap, 2009-2012
(Medicare Payment Advisory Commission, 2012, 2013, 2014, 2015)
16%$
14%$

14%$

13%$

13%$

12%$

12%$
2009$

10%$

2010$

8%$

2011$

6%$

2012$

4%$
2%$
0%$

Table 28. Medicare Part D Plan Enrollment Trends, 2007 – 2014 (Medicare Payment
Advisory Commission, 2015)
Average
Annual
Growth
Rate
2007
2008
2010
2012
2014
2007-2014
Total Part D enrollment
(in millions)
24.2
25.6
27.6
31.5
37.4
6%
Percent of Medicare
enrollees
54%
56%
58%
60%
69%
LIS (in millions)
9.4
9.6
9.9
10.8
11.4
3%
Non-LIS (in millions)
14.8
16.0
17.1
10.7
26.0
8%
Percent receiving the
LIS
39%
38%
36%
34%
30%
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The percent of health plan members who reached the gap in this study fell within
a broad range, likely due to the strict limitations for inclusion (i.e., fill in January, fill at
mail order, diabetic medications only). In this study, the increase in the percentage of
health plan members reaching the gap year over year may be due in part to the rising cost
and increased availability of branded medications in the diabetic class. During the study
period, there were a total of six branded medications that lost their patent and had generic
medications launch, which increases competition and drives down the medication price.
However, there were thirteen FDA approvals and brand medications that launched during
this period. Brand medications are expensive and could increase spending to move people
into the coverage gap. Figure 21 shows the movement of brand medications and patent
losses in the market over the study period along with the percent of health plan members
who reached the gap.
Figure 21. Percent of health plan members who reached the gap with brand launches and
patent losses
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The 2014 Drug Trend Report produced by The Express Scripts Lab stated that the
diabetes medication category experienced a higher per-member-per-year (PMPY) spend
($358.93) than any other traditional therapy class among Medicare enrollees (The
Express Scripts Lab, 2015). This represented a 26.4% increase in trend over 2013, mainly
due to unit cost (21.5%). While popular branded drugs like nateglinide (brand name
Starlix), pioglitazone (brand name Actos), pioglitazone hydrochloride/metformin
hydrochloride (brand name Actosplus MET), glimepiride/pioglitazone (brand name
Duetact), rosiglitazone (brand name Avandia) and repaglinide (brand name Prandin) lost
patent and became available in a generic form during the study period, they were
replaced by new branded medications. Table 29 contains the specific diabetic
medications approved by the U.S. Food and Drug Administration during the study period.
Table 29. Insulin and diabetic medications approved between 2009 – 2014 (U.S. Food
and Drug Administration, 2015)
Drug Class
Brand Name
Generic Name
Approval Date
DPP-4
Onglyza
saxagliptin
July 2009
GLP-1
Victoza
liraglutide
January 2010
DPP-4
Kombiglyze XR saxagliptin/metformin
November 2010
DPP-4
Tradjenta
linagliptin
May 2011
DPP-4
Juvisync
sitagliptin/simvistatin
October 2011
GLP-1
Bydureon
exenatide synthetic
January 2012
DPP-4
Jentadueto
linagliptin/metformin
February 2012
DPP-4
Janumet XR
sitagliptin/metformin
February 2012
SGLT-2
Farxiga
dapagliflozin
January 2014
GLP-1
Tanzeum
abilglutide
May 2014
Insulin
Afrezza
insulin human
June 2014
Inhalation
Powder
SGLT-2
Jardiance
empagliflozin
August 2014
GLP-1
Trulicity
duglaglutide
September 2014
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In addition to the market entry of new branded products, highly utilized
medications saw double-digit increases in unit-cost trend, including insulin glargine
[rDNA origin] (brand name Lantus) and sitagliptin (brand name Januvia) (The Express
Scripts Lab, 2015). Although insulin was excluded from adherence calculations in this
study, the cost did contribute to a member reaching the coverage gap. As presented in
Table 11, the average member cost of the brand diabetic medication index fill increased
from $40.38 in 2009 to $58.80 in 2014.
The graph in Figure 22 depicts the prescription price index of brand and generic
medications utilizing 2008 dollars as a baseline. As stated in the 2014 Drug Trend
Report, “from the base price of $100.00 set in January 2008, in December 2014 prices for
the most commonly used generic medications decreased to $37.13 (in 2008 dollars) and
prices for the most commonly used brand medications increased to $227.39 (in 2008
dollars). In contrast, a market basket of commonly used household goods costing $100.00
in 2008, as measured by the Bureau of Labor Statistics (BLS) Consumer Price Index,
grew to only $111.24 (in 2008 dollars) by December 2014 (The Express Scripts Lab,
2015). “
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Figure 22. The Express Scripts Prescription Price Index (The Express Scripts Lab, 2015)

Pre-coverage gap and within coverage gap medication adherence
The first objective of the study was to evaluate diabetes medication adherence of
health plan members before they reach the coverage gap and then while they are in the
coverage gap. The study participants were separated into two cohorts by brand and
generic medication utilization. The results of this study indicate that health plan members
using brand medications decreased medication adherence once they entered the coverage
gap for all years. The brand cohort also had a decrease in medication adherence year over
year both before the health plan members entered the coverage gap and while in the
coverage gap as presented in Figure 23. As shown in Table 9, the difference in the mean
between the pre-gap adherence and within-gap adherence decreased from 2009 (0.040) to
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2014 (0.030). In other words, although adherence was decreasing once health plan
members entered the gap, the decline was less in 2014.
Figure 23. Medication adherence pre-coverage gap and while in the coverage gap for the
brand cohort
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In the generic cohort, there was observed a decline in medication adherence once
health plan members entered the coverage gap. Medication adherence prior to entering
the coverage gap remained relatively flat year over year while adherence in the coverage
gap fluctuated as shown in Figure 24. They also exhibited a decrease in the difference in
the mean between the pre-gap adherence and within-gap adherence over the study period.
As shown in Table 10, the mean for 2009 was 0.025 and decreased to 0.009 in 2014.
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Figure 24. Medication adherence pre-coverage gap and while in the coverage gap for the
generic cohort
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These findings are consistent with other published studies. A decrease in
adherence to medications in the coverage gap was reported in studies conducted by Gu, et
al., Li, et al., Sacks, et al. and Zhang, et al (Gu, Zeng, Patel, & Tripoli, 2010; Li et al.,
2012; Sacks et al., 2013; Zhang et al., 2013). Researchers in Zhang’s study also found
that health plan members with generic coverage in the coverage gap decreased brand
utilization significantly and generic utilization slightly, even though generic medications
were covered under their prescription drug benefit. The Kaiser Family Foundation
published a study finding that among Part D health plan members using medications for
diabetes who reached the coverage gap in 2007, 10 percent stopped taking their diabetes
medication and 5 percent reduced their medication use (Hoadley, Hargrave, et al., 2008).
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Demographics for propensity score matched groups
The second objective was to compare diabetes medication adherence between two
similar groups with differing benefit structures, one group with a gap in coverage as
opposed to a group with no benefit changes within the year. Health plan members eligible
for a low-income subsidy (LIS) were used as the control group. Health plan members
with no benefit once reaching the coverage gap were used as the treatment group. The
unmatched groups exhibited a great degree of variation. As a result, propensity score
matching was conducted using age, race and sex as covariates. Both groups filled a
diabetic medication at Humana’s mail order pharmacy in January of the respective plan
year. In addition, both groups had total drug costs that would qualify them to reach the
Medicare Part D coverage gap in the respective plan years albeit the control group did not
incur the actual costs associated with reaching the coverage gap. The control and
treatment groups were equalized but some variability remained across years. Treatment
group demographics across plan years are displayed in Tables 30-31.

Table 30. Demographics across plan years for treatment group using brand medications
2009
2010
2011
2012
2013
2014
Age
69.1
71.1
69.1
72.0
71.7
69.5
(mean)
Female
59.3%
56.9%
64.4%
77.0%
87.6%
66.7%
White
77.8%
72.4%
84.2%
92.2%
88.4%
82.2%
Table 31. Demographics across plan years for treatment group using generic medications
2009
2010
2011
2012
2013
2014
Age
70.6
70.7
70.7
68.6
69.3
68.5
(mean)
Female
50.0%
61.5%
69.1%
58.2%
70.1%
66.2%
White
88.9%
82.1%
74.1%
88.8%
90.5%
83.3%
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Medication adherence in control and treatment groups
	
  
In general, the control group exhibited better medication adherence than the
treatment group as displayed in Figures 25-26. These results align with other published
studies. Researchers of a cross-sectional, retrospective analysis using claims from 20052006 showed LIS health plan members had better diabetic medication adherence (62.5%)
than non-LIS health plan members with no coverage gap benefit (57.7%) (Yala et al.,
2014). In a retrospective cohort study using data from the U.S. Renal Data System
(USRDS), researchers examined medication adherence for Medicare-eligible dialysis
patients (Park et al., 2014). The health plan members were separated into four groups:
Cohort 1 consisted of those that did not reach the coverage gap, Cohort 2 entered the
coverage gap, Cohort 3 had spending to qualify catastrophic coverage and Cohort 4 were
LIS members. Health plan members in cohort 2 on diabetic medications had a significant
decrease in medication adherence once they entered the coverage gap (72.4% vs. 57.9%).
In addition, LIS members had statistically significant better diabetic medication
adherence than non-LIS members who reached the coverage gap (67.8% vs. 65.7%).
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Figure 25. Medication adherence of the control and treatment groups for the brand cohort

	
  
Figure 26. Medication adherence of the control and treatment groups for the generic
cohort
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Medication adherence across plan years
The third objective was to examine the diabetes medication adherence trend over
multiple years as the coverage gap is closed. As Table 3 outlined, the member cost share
in the coverage gap began to decrease starting in 2010 but at the same time for most years
the initial deducible, the threshold to enter the coverage gap and the catastrophic phase
entry threshold all increased. This means health plan members faced the possibility of
higher out of pocket costs before reaching the coverage gap.
The adherence for the control group, both brand and generic cohorts contained
very little fluctuation year over year. Treatment group adherence for brand medications
increased in year 2010 but then showed a decline each additional year. Treatment group
adherence for generic medications fluctuated but showed an overall decrease from year
2009.
Although multiple studies have been conducted on the effect of the Part D
coverage gap on medication adherence, few studies exist that examine the effect of
closing the coverage gap. In a study conducted by Zeng, et al., researchers found
adherence of health plan members in a national Pharmacy Benefit Manager (PBM)
increased from 2010 to 2011 as the coverage gap initially began to close (Zeng et al.,
2013). Additionally, in a study conducted by Brown, et al. initial data from another
national PBM indicated adherence was modestly improving across plan years from 2009
to 2011 for brand medications (Brown et al., 2012).
A possible explanation for the finding that adherence is decreasing as the
coverage gap is closing could be the limitation of the study population to mail order
utilizers. In a literature search conducted by Cramer on findings from 1966 – 2003,
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overall oral diabetic medication adherence was found to range from 36 – 93 percent
(Cramer, 2004). In another literature review conducted by DiMatteo, mean diabetic
medication adherence from 23 studies was found to be 67.5 percent (DiMatteo, 2004).
Finally, Express Scripts reports average diabetic therapy adherence at 79.1 percent (2009)
and 79.2 percent (2010) (The Express Scripts Lab, 2010, 2011). However, studies have
shown when segregated, mail order utilizers have higher adherence than health plan
members who fill at retail pharmacies. In 2011, Khandelwal, et al. noted no significant
adherence difference in 90-day at retail verses mail order utilization except in the diabetic
medication class (80.2 vs. 83.1 percent) (Khandelwal et al., 2011). Researches using
diabetic patient data from Kaiser Permanente Northern California reported similar results,
mail order (84.7 percent) versus retail pharmacy (76.9 percent) (Duru et al., 2010).
Finally, in 2014 researchers presented data showing a significant difference in diabetic
medication adherence in mail order (90.9 percent) versus retail (66.8 percent) (Iyengar &
Lefrancois, 2014). By limiting the study population to mail order utilizers who already
exhibit a high medication adherence, the opportunity to identify significant changes in
adherence may have been hindered.
However, the study findings indicate a decrease in adherence rather than the
expected increase associated with reducing the coverage gap cost barrier. Although the
coverage gap amount was decreasing during the study period, there were additional cost
pressures from medication price inflation, increases in benefit caps and a downturn in the
economy. As noted in the 2011 Drug Trend Report, “intensity, changes in adherence to
medication, has suffered during the recent economic downturn as some patients have
reacted to financial stress by foregoing their medications or taking them less frequently
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than prescribed to save money. We anticipate that intensity will increase as the economy
improves.” (The Express Scripts Lab, 2012)
Finally, cost is only one determinant of patient adherence. Piette, et al. described
the cost-adherence relationship as “modified by contextual factors, including patients'
characteristics (e.g., age, ethnicity, and attitudes toward medications), the type of
medications they are using (e.g., the complexity of dosing and the drug's clinical target),
clinician factors (e.g., choice of first-line agent and communication about medication
costs), and health system factors (e.g., efforts to influence clinicians' prescribing and to
help patients apply for financial assistance programs) (Piette, Heisler, Horne, & Caleb,
2006).”

Strengths and Limitations
Evidence from the literature suggests that health plan members reduce the use of
medications while in the coverage gap. This study is one of only a few to examine health
plan data while the coverage gap is closing due to the ACA and the only one to cover six
years.
The study design accounts for different types of effects that can introduce biases
in our estimates. First, in assessing objective 1 (medication adherence rates during the
gap), eligible health plan members were used as their own controls. Since the same
cohort of patients is observed before and after the intervention, this reduces potential bias
introduced due to differences in beneficiary characteristics between the study periods.
Second, this study used the pre-post-with-a-comparison-group design to assess objectives
2 and 3, the strongest quasi-experiment observational study design. The benefit to this
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approach was that the drug coverage in the control group did not change in the pre-gap
and within-gap periods, while treatment groups were exposed to a sudden increase in
medication price. Even though the control group was different in socioeconomic status
from the treatment groups, all groups had similar baseline trends in diabetic medication
use.
The study is not without limitations. The use of retrospective claims data implies
that the study is affected by limitations related to secondary data sources. One significant
limitation is the assumption that filled prescriptions were taken as prescribed. Another
limitation of claims data is the lack of visibility into physician dispensed samples or cash
prescriptions. This study was limited to only one health plan, although the health plan had
the second largest national share of Medicare Part D membership during the study period.
This study was also limited to health plan members using diabetic medications at
Humana’s mail order facility and therefore may not generalize to the broader population.

Findings and recommendations for future research
The results of this study indicate that being in the coverage gap was a significant
indicator of a decrease in adherence for health plan members on brand diabetic
medications. This was apparent when evaluating pre-gap versus within-gap adherence
and when the cohort was compared to a control group. Although the generic cohort did
not show significant differences for all years, the cohort did show a decrease in adherence
while in the coverage gap. Both cohorts also exhibited a decrease in the difference
between pre-gap verses within-gap adherence from 2009 to 2014, which could indicate
the closing of the coverage gap is beginning to have an effect on within-gap behavior. In
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other words, in later years health plan members had a less significant drop in adherence
rates once they entered the coverage gap and this could be due to the ACA lessening the
impact of the coverage gap.
While the study findings showed a decrease rather than an increase in the
treatment group medication adherence year over year, the results did indicate no
significant changes in the control group. The expectation would be that once the coverage
gap is fully closed in 2020, the treatment group would exhibit similar behavior. Both
groups exhibited high adherence overall suggesting the mail order dispensing channel
could have an effect on adherence.
Limiting the population to mail order utilizers was an unintended potentially
important variable in this study. Studies have shown that mail order utilizers have
considerably higher adherence than health plan members who utilize retail pharmacies.
One reason for higher adherence at mail order could be the automatic refill option
available at many mail order pharmacies where refills are shipped without the health plan
member requesting it. This could result in an inflated adherence rate because the
medication is shipped whether the member needs it or not. It should be noted that
Humana’s mail order pharmacy does not offer automatic refills for Medicare Part D
members. They do have reminder calls but the health plan member must take some action
on their part and opt in to order a refill.
Because dispensing channel was an unintended variable, it was not included in the
theoretical model discussion, specifically Andersen’s Behavioral Model. In the model,
enabling resources are factors that support or impede the use of health services. For
example, the type of health insurance is considered an enabling resource. Dispensing
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channel would be classified as an enabling resource in the model considering it affects
the method by which a health plan member accesses their medication. It would be
considered a highly mutable factor because it can be changed from a retail pharmacy to
mail order or even to a physician office or hospital.
Future research should examine the effect of the coverage gap once it is fully
closed in 2020 and it is possible to take an even broader view of the coverage gap impact.
As evidence from the literature suggests, decreases in medication adherence can result in
poor clinical outcomes, which can increase the total cost of care. Therefore, in addition to
adherence, future research should be directed at studying the impact of the Medicare Part
D coverage gap on utilization of other health care services like diagnostic tests, physician
office utilization, emergency room visits and hospitalizations. Finally, more attention
should be given to the dispensing channel and it’s possible effect on medication
adherence. Future research should focus on whether mail order utilization promotes better
medication adherence or if better adherers choose mail order.

Summary
	
  
This	
  study	
  is	
  important	
  and	
  relevant	
  because	
  it	
  is	
  one	
  of	
  the	
  only	
  studies	
  
identified	
  that	
  utilized	
  6	
  years	
  of	
  data	
  related	
  to	
  the	
  closing	
  of	
  the	
  coverage	
  gap.	
  
While	
  the	
  results	
  failed	
  to	
  show	
  the	
  closing	
  of	
  the	
  coverage	
  gap	
  as	
  having	
  an	
  impact	
  
on	
  improving	
  adherence	
  in	
  this	
  group	
  over	
  multiple	
  years,	
  it	
  was	
  determined	
  that	
  
entering	
  the	
  coverage	
  gap	
  decreased	
  adherence	
  and	
  the	
  additional	
  cost	
  pressures	
  in	
  
the	
  form	
  of	
  increasing	
  coverage	
  limits	
  and	
  price	
  inflation	
  may	
  have	
  offset	
  any	
  good	
  
closing	
  the	
  coverage	
  gap	
  is	
  doing	
  in	
  these	
  diabetic	
  patients.	
  This	
  study	
  also	
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highlights	
  the	
  complexity	
  of	
  medication	
  adherence	
  and	
  the	
  need	
  for	
  additional	
  
research	
  in	
  this	
  area.	
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APPENDIX I
GLOSSARY
Coverage gap: A benefit phase in Medicare Part D where the enrollee incurs all or most
of the drug cost until they hit a certain coverage limit

Low-income subsidy (LIS): Medicare beneficiaries who qualify for assistance in paying
for their Part D monthly premium, annual deductible, coinsurance, and copayments

Medicare Advantage prescription drug plan (MAPD): a drug benefit offered as part of
a Medicare replacement plan

Medicare Modernization Act (MMA): Legislation passed in 2003 allowing Medicare
expansion in 2006 to offer voluntary outpatient prescription drug coverage

Pharmacy Quality Alliance (PQA): A consensus-based, multi-stakeholder membership
organization committed to improving health care quality and patient safety with a focus
on the appropriate use of medications

Prescription drug plan (PDP): A drug benefit offered as a supplement to standard
Medicare
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Propensity score matching (PSM): A statistical matching technique that attempts to
estimate the effect of a treatment, policy or other intervention by accounting for the
covariates that predict receiving the treatment

Proportion of days covered (PDC): A measurement period covered by prescription
claims for the same medication or another in its therapeutic category

True-out-of-pocket-spending (TrOOP): Only costs incurred and paid by the health plan
member, those prescription drug costs that count toward the annual out- of-pocket
threshold that health plan members must reach before the catastrophic drug benefit phase
begins
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